Overview
The main aim of this study is to compare the HAE attack rate requiring on-demand treatment before and within 2 years after participants with HAE have been treated with lanadelumab.
This study is conducted in the United Kingdom where participants were treated or about to be treated with landelumab according to their routine practice at hospitals. Data will be directly collected from participants via study diaries, questionnaires, their medical records, and study doctors treating them. Participants will be contacted every 3 months during study participation (via phone).
Eligibility
- Inclusion
-
- Documented diagnosis of HAE type I or II (confirmed through laboratory testing)
- Documented initiation of treatment with lanadelumab
- Greater than or equal to (≥)12 years of age at initiation of treatment with lanadelumab
- ≥12 months of continuous medical record data before initiation of treatment with
lanadelumab
- Exclusion
• Exposure to lanadelumab administered as an investigation product in a clinical trial
setting at any point in time